Warning letter
Infuscience, Inc. dba Bioscrip Infusion Services: warning letter of Dec 21, 2020
FDA warning letter 609526 · Division of Pharmaceutical Quality Operations I
Key facts
| Reference number | 609526 |
|---|---|
| Company | Infuscience, Inc. dba Bioscrip Infusion Services |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Dec 21, 2020 |
| Posted date | Jan 12, 2021 |
| Issuing office | Division of Pharmaceutical Quality Operations I |
| Product type | Drugs |
| Inspection city | Chantilly |
| Inspection ZIP | 20151-1230 |
| Inspection start date | Jul 23, 2019 |
| Letter on fda.gov | fda.gov |
At a glance
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: